2 days Ago By ABMN Staff
American Century Companies Inc. increased its stake in shares of Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT – Free Report ) by 10.
7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,018 shares of the biotechnology company’s stock after buying an additional 4,547 shares during the quarter. American Century Companies Inc.
’s holdings in Arcturus Therapeutics were worth $798,000 as of its most recent SEC filing. Other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC boosted its holdings in Arcturus Therapeutics by 45.
0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 3,705 shares during the last quarter. Spire Wealth Management raised its stake in Arcturus Therapeutics by 393.
3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 10,746 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Arcturus Therapeutics by 954.
7% in the third quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company’s stock worth $367,000 after buying an additional 14,330 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Arcturus Therapeutics in the third quarter valued at approximately $420,000.
Finally, Tocqueville Asset Management L.P. grew its holdings in Arcturus Therapeutics by 42.
7% in the 4th quarter. Tocqueville Asset Management L.P.
now owns 22,400 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 6,700 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets A number of research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a report on Thursday.
Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Canaccord Genuity Group cut their target price on shares of Arcturus Therapeutics from $74.00 to $68.
00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $58.00 to $50.
00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Finally, BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 10th.
Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $59.20.
Arcturus Therapeutics Trading Up 3.7 % Shares of ARCT opened at $9.70 on Friday.
The stock’s 50 day moving average is $13.89 and its two-hundred day moving average is $16.89.
The firm has a market capitalization of $263.06 million, a PE ratio of -4.37 and a beta of 3.
41. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.
04 and a twelve month high of $45.00. Arcturus Therapeutics ( NASDAQ:ARCT – Get Free Report ) last posted its earnings results on Thursday, March 6th.
The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.
78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.
39%. The firm had revenue of $22.77 million for the quarter, compared to analysts’ expectations of $44.
64 million. On average, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.
22 EPS for the current year. About Arcturus Therapeutics ( Free Report ) Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Featured Stories Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT – Free Report ).
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
